Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12565036 | 0.81 | TDP1 (0.42) | TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15537216 | 0.77 | TSHR (0.39) | TSHRTDP1ALDH1A1 | |
| SCHEMBL7498173 | 0.76 | TDP1 (0.37) | TDP1 | |
| SCHEMBL6351731 | 0.76 | TDP1 (0.42) | CYP2D6TDP1 | |
| SCHEMBL4013581 | 0.74 | GAA (0.43) | TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12342993 | 0.74 | TDP1 (0.36) | TDP1 | |
| SCHEMBL8281605 | 0.73 | ALDH1A1 (0.40) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL18922845 | 0.73 | ACLY (0.39) | CYP2C19HIF1ACYP2D6TSHRTDP1 | |
| SCHEMBL2792859 | 0.72 | — | — | |
| SCHEMBL6662491 | 0.71 | ALDH1A1 (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9910354-B2 | Resist underlayer film-forming composition and method for forming resist pattern using the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-03-06 | — | — | US | disclosed |
| US-20170045820-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION AND METHOD FOR FORMING RESIST PATTERN USING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9448480-B2 | Resist underlayer film formation composition and method for forming resist pattern using the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160238936-A1 | RESIST UNDERLAYER FILM FORMATION COMPOSITION AND METHOD FOR FORMING RESIST PATTERN USING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-8962234-B2 | Resist underlayer film forming composition and method for forming resist pattern using the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| EP-1238704-B1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEM (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-1433527-B1 | CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | DAICEL CHEM (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-7759515-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| CN-100537031-C | Processes for production of organic compounds | DAICEL CHEM (JP) | 2009-09-09 | — | — | CN | disclosed |
| US-6998491-B2 | Catalyst comprising a cyclic imide compound | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20060030716-A1 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | ISHII YASUTAKA | 2006-02-09 | — | — | US | disclosed |
| US-20050020439-A1 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1459804-A1 | CATALYSTS COMPRISING CYCLIC ACYLUREA COMPOUNDS AND PROCESSES FOR PRODUCTION OF ORGANIC COMPOUNDS WITH THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1433527-A1 | CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040053778-A1 | Catalyst comprised of n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| US-20020128149-A1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1238704-A2 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | Daicel Chemical Industries, Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128149-A1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | NOX4, POR, NOX1 | HMGCR 2104/4885CHRM1 1680/4885TBXA2R 2713/4885 |
| US-20060030716-A1 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | MOGAT2, HAT1, ACOX1 | HMGCR 537/4885CHRM1 3154/4885TBXA2R 1086/4885 |
| US-20050020439-A1 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | MOGAT2, ACSS2, ACOX1 | HMGCR 619/4885CHRM1 3161/4885TBXA2R 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.